Skip to content
Politically.com Search all
Menu

2025 · 2nd Quarter (Apr 1 - June 30)

ACURX PHARMACEUTICALS, INC.

Filed by INNOVATIVE FEDERAL STRATEGIES, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 18, 2025
Income
$30,000.00
Expenses
Not reported
Filing UUID
9fc592c4-b9f1-4890-b3ae-bc1ae783e7bf
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

H.R.4026/S.____, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.____/S.____, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.

Literal federal measure citations: H.R.4026

DEF · Defense

H.R.____/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.

Literal federal measure citations: S.2296

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.